Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Paolo Carlini(National Cancer Institute), E. Terzoli(Catholic University of America), Emilio Bria(Università Cattolica del Sacro Cuore), Alessandra Felici, Alessandra Fabi(Agostino Gemelli University Polyclinic), Enzo Maria Ruggeri, Fabiana Letizia Cecere, Francesco Cognetti(Apple (Israel)), Carmen Nuzzo, Alain Gelibter(Policlinico Umberto I), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), Mariangela Ciccarese, Michèle Milella(National Cancer Institute)
Cited by 38
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
PTEN: Multiple Functions in Human Malignant Tumors
|Frontiers in Oncology|2015|460